CN106715444B - 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途 - Google Patents

新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途 Download PDF

Info

Publication number
CN106715444B
CN106715444B CN201580045432.7A CN201580045432A CN106715444B CN 106715444 B CN106715444 B CN 106715444B CN 201580045432 A CN201580045432 A CN 201580045432A CN 106715444 B CN106715444 B CN 106715444B
Authority
CN
China
Prior art keywords
disease
compound
disorders
disorder
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580045432.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106715444A (zh
Inventor
德尔菲娜·沙尔万
巴蒂斯特·曼特奥
文森特·波梅尔
弗兰乔斯·孔凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prexton Therapeutics SA
Original Assignee
Prexton Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prexton Therapeutics SA filed Critical Prexton Therapeutics SA
Priority to CN201910567865.9A priority Critical patent/CN110343118A/zh
Publication of CN106715444A publication Critical patent/CN106715444A/zh
Application granted granted Critical
Publication of CN106715444B publication Critical patent/CN106715444B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580045432.7A 2014-08-27 2015-08-27 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途 Expired - Fee Related CN106715444B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910567865.9A CN110343118A (zh) 2014-08-27 2015-08-27 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182468.0 2014-08-27
EP14182468 2014-08-27
PCT/EP2015/069601 WO2016030444A1 (en) 2014-08-27 2015-08-27 Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910567865.9A Division CN110343118A (zh) 2014-08-27 2015-08-27 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途

Publications (2)

Publication Number Publication Date
CN106715444A CN106715444A (zh) 2017-05-24
CN106715444B true CN106715444B (zh) 2019-07-12

Family

ID=51421865

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580045432.7A Expired - Fee Related CN106715444B (zh) 2014-08-27 2015-08-27 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途
CN201910567865.9A Pending CN110343118A (zh) 2014-08-27 2015-08-27 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910567865.9A Pending CN110343118A (zh) 2014-08-27 2015-08-27 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途

Country Status (26)

Country Link
US (3) US10017521B2 (cg-RX-API-DMAC7.html)
EP (3) EP3502115A1 (cg-RX-API-DMAC7.html)
JP (1) JP6430015B2 (cg-RX-API-DMAC7.html)
KR (1) KR101870589B1 (cg-RX-API-DMAC7.html)
CN (2) CN106715444B (cg-RX-API-DMAC7.html)
AU (1) AU2015308438B2 (cg-RX-API-DMAC7.html)
CA (1) CA2956191C (cg-RX-API-DMAC7.html)
CY (1) CY1121352T1 (cg-RX-API-DMAC7.html)
DK (1) DK3186257T3 (cg-RX-API-DMAC7.html)
ES (1) ES2714073T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190343T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041941T2 (cg-RX-API-DMAC7.html)
IL (1) IL250287B (cg-RX-API-DMAC7.html)
LT (1) LT3186257T (cg-RX-API-DMAC7.html)
MA (3) MA52702A (cg-RX-API-DMAC7.html)
ME (1) ME03339B (cg-RX-API-DMAC7.html)
MX (1) MX369643B (cg-RX-API-DMAC7.html)
NZ (1) NZ728853A (cg-RX-API-DMAC7.html)
PL (1) PL3186257T3 (cg-RX-API-DMAC7.html)
PT (1) PT3186257T (cg-RX-API-DMAC7.html)
RS (1) RS58592B1 (cg-RX-API-DMAC7.html)
RU (1) RU2672569C2 (cg-RX-API-DMAC7.html)
SI (1) SI3186257T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900152T1 (cg-RX-API-DMAC7.html)
TR (1) TR201903332T4 (cg-RX-API-DMAC7.html)
WO (1) WO2016030444A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110343118A (zh) * 2014-08-27 2019-10-18 普雷克斯顿医疗股份公司 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180041234A (ko) 2015-08-27 2018-04-23 프렉스톤 테라퓨틱스 에스에이 레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787723A1 (en) * 1994-10-21 1997-08-06 Suntory Limited Cyclopropachromenecarboxylate derivatives
WO2004092154A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CN102812014A (zh) * 2009-10-30 2012-12-05 多美恩医疗公司 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
US20070027216A1 (en) 2005-07-15 2007-02-01 Bridget Larson Novel hydrochloride salts of levodopa
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
US20100144756A1 (en) 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
EP2804870B1 (en) * 2012-01-18 2016-11-30 ADDEX Pharma S.A. 2-AMINO-4,5,6,8-TETRAHYDROPYRAZOLO[3,4-b]THIAZOLO [4,5-d]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
AU2015308438B2 (en) * 2014-08-27 2018-12-13 Prexton Therapeutics Sa Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
KR20180041234A (ko) 2015-08-27 2018-04-23 프렉스톤 테라퓨틱스 에스에이 레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787723A1 (en) * 1994-10-21 1997-08-06 Suntory Limited Cyclopropachromenecarboxylate derivatives
WO2004092154A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CN102812014A (zh) * 2009-10-30 2012-12-05 多美恩医疗公司 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"DIOXANE ANALOGS OF FLAVYLIUM SALTS";V. V. Ishehenko et al.;《Chemistry of Heterocyclic Compounds》;19951231;第31卷(第3期);第276-278页 *
"Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators";Colleen M. Niswender et al.;《Bioorganic & Medicinal Chemistry Letters》;20080829;第18卷;第5626-5630页 *
"SYNTHETIC ANALOGS OF NATURALLY OCCURRING FLAVOLIGNANS. X. REACTION OF FLAVONES AND THEIR THIODERIVATIVES WITH HYDROXYLAMINE";A. Aitmambetov et al.;《Chemistry of Natural Compounds》;20001231;第36卷(第1期);第47-50页 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110343118A (zh) * 2014-08-27 2019-10-18 普雷克斯顿医疗股份公司 新型色酮肟衍生物以及其作为代谢型谷氨酸受体的别构调节剂的用途

Also Published As

Publication number Publication date
ES2714073T3 (es) 2019-05-27
IL250287B (en) 2020-02-27
IL250287A0 (en) 2017-03-30
RU2672569C2 (ru) 2018-11-16
CY1121352T1 (el) 2020-05-29
NZ728853A (en) 2018-04-27
MA48048A (fr) 2020-02-12
RS58592B1 (sr) 2019-05-31
US10442818B2 (en) 2019-10-15
US20170253613A1 (en) 2017-09-07
JP6430015B2 (ja) 2018-11-28
EP3186257A1 (en) 2017-07-05
SI3186257T1 (sl) 2019-07-31
MX369643B (es) 2019-11-15
EP3502115A1 (en) 2019-06-26
MX2017002429A (es) 2017-08-02
DK3186257T3 (en) 2019-04-01
JP2017525776A (ja) 2017-09-07
RU2017109818A (ru) 2018-10-01
CA2956191A1 (en) 2016-03-03
EP3186257B1 (en) 2019-02-06
US10017521B2 (en) 2018-07-10
PL3186257T3 (pl) 2019-07-31
US20180291034A1 (en) 2018-10-11
CN106715444A (zh) 2017-05-24
MA40530A (fr) 2017-07-05
PT3186257T (pt) 2019-03-27
MA52702A (fr) 2021-03-31
EP3696183A1 (en) 2020-08-19
HRP20190343T1 (hr) 2019-05-31
CN110343118A (zh) 2019-10-18
ME03339B (me) 2019-10-20
CA2956191C (en) 2020-01-28
KR101870589B1 (ko) 2018-06-25
TR201903332T4 (tr) 2019-03-21
HUE041941T2 (hu) 2019-06-28
AU2015308438B2 (en) 2018-12-13
AU2015308438A1 (en) 2017-03-02
US20200024285A1 (en) 2020-01-23
LT3186257T (lt) 2019-04-25
WO2016030444A1 (en) 2016-03-03
RU2017109818A3 (cg-RX-API-DMAC7.html) 2018-10-01
KR20170042624A (ko) 2017-04-19
SMT201900152T1 (it) 2019-05-10

Similar Documents

Publication Publication Date Title
US11008323B2 (en) Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
CA2903107C (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
EP3341380B1 (en) Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
US20200024285A1 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
TW202423910A (zh) 化合物
HK40010218A (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HK1233257B (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HK1233257A1 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
JP2017095411A (ja) ピラゾール誘導体の塩の結晶
KR20250110875A (ko) MGLU7 수용체의 음성 알로스테릭 조절제로서의 신규한 피롤로[1,2-d][1,2,4]트라이아진-1-온 유도체
HK1249904B (en) Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
HK1249904A1 (en) Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190712

Termination date: 20210827

CF01 Termination of patent right due to non-payment of annual fee